On September 18, 2025, researchers at UC Davis Health unveiled groundbreaking findings regarding bone health, specifically in relation to steroid use. Their work highlights the role of a protein known as Basigin, which is activated in skeletal stem cells under glucocorticoid treatment, positing it as a key player in the adverse effects of steroids on bone density and tissue integrity. The research, published in Nature Communications, opens new avenues for therapeutic strategies aimed at preserving bone health in patients requiring long-term steroid therapy.

Understanding the Impact of Glucocorticoids

Glucocorticoids, such as prednisone, are commonly prescribed for a variety of medical conditions, including:

  • Asthma
  • Arthritis
  • Autoimmune diseases
  • COVID-19 treatment

While these treatments are vital in managing these conditions, they possess a significant risk of bone weakening and a heightened fracture risk due to their anti-osteogenic effects. This research examines how glucocorticoids interfere with the functioning of skeletal stem cells, causing damaging shifts in bone formation and blood vessel integrity.

The Role of Basigin in Bone Health

The activated Basigin protein significantly disrupts the normal dynamics between skeletal stem cells and blood vessel cells in bones, leading to:

Effect Description
Bone Loss Reduction in bone density due to impaired stem cell function.
Abnormal Blood Vessel Formation Disruption of angiogenesis, which is crucial for bone health.

According to Thomas H. Ambrosi, assistant professor in Orthopedic Surgery and co-corresponding author, “Identifying Basigin as a driver of bone deterioration opens the door to targeted therapies that could help patients maintain strong, healthy bones—even while undergoing long-term glucocorticoid treatment.”

Blocking Basigin: A Promising Strategy

The researchers employed a dual approach in their experiments: using an antibody to block the Basigin protein and genetically removing it from skeletal cells. The outcomes were promising:

  • Blocking Basigin not only prevented further bone loss but also restored bone strength.
  • Older mice, identified for having diminished skeletal health, demonstrated significant improvements in bone mass following treatment with the Basigin-blocking antibody.

These findings suggest that a therapeutic focus on Basigin could lead to novel treatment options for a range of conditions including age-related osteoporosis and other forms of tissue damage associated with aging.

Implications for Future Treatment

This research not only focuses on the biological underpinnings of steroid-induced bone loss but also its broader implications in clinical practice:

Condition Treatment Implications
Age-Related Osteoporosis Potential new therapies that enhance bone strength while patients are on glucocorticoids.
Steroid-Induced Bone Damage Targeting Basigin could lead to better preservation of bone health during necessary steroid treatments.

Nancy E. Lane, distinguished professor of rheumatology at UC Davis Health and corresponding author of the study, emphasized that these insights can significantly improve the quality of life for millions of patients who rely on steroids for chronic conditions.

Conclusion

The identification of Basigin as a detrimental factor in steroid-related bone health represents a critical advancement in the field of osteology. As the research progresses, further exploration into targeted therapies may yield effective strategies for maintaining bone integrity in at-risk populations.

More information: Basigin links altered skeletal stem cell lineage dynamics with glucocorticoid-induced bone loss and impaired angiogenesis, Nature Communications (2025).

For deeper insight and related studies, consider the following references:

  • Ambrosi, T. H. et al. (2025). Basigin links altered skeletal stem cell lineage dynamics with glucocorticoid-induced bone loss. Nature Communications.
  • Lane, N. E. (2025). Glucocorticoids, bone health, and therapies. Journal of Bone Research.